IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

Authors :: Ghosh, Nilanjan
Zinzani, Pier Luigi
Samaniego, Felipe
Jurczak, Wojciech
Derenzini, Enrico
Reeves, James A.
Knopinska-Posluszny, Wanda
Cheah, Chan Y.
Phillips, Tycel
Lech-Maranda, Ewa
Cheson, Bruce
Calmi, Paolo
Grosicki, Sebastian
Leslie, Lori A.
Chavez, Julio C.
Fonseca, Gustavo
Babu, Sunil
Hodson, Daniel J.
Shao, Spencer H.
Burke, John M.
Source :: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS404-S404, 1p
Publication Year :: 2021

Full Text Access

Tools